for chronic pain relief.
Case Studies
technology mean there are
now better solutions for
chronic pain relief.
This is the first prospective study looking at the performance of the SCS E-Tool compared to the expertise of a group of experienced Italian Neuromodulators in predicting the appropriateness and long-term outcomes of SCS. The E-tool performed better. Demartini L., Mazzoleni S., Thomson S., Conversa G., Bettaglio R., Malovini A.L., Bonezzi C. 2026. Utility of an eHealth Tool in the Selection of Patients to Be Treated With Spinal Cord Stimulation: Experience of an Italian Pain Unit. Neuromodulation 2026; ■: 1–9.
Spinal_Cord_Stimulation_1687604884
This is now published in European Journal of Pain. Please activate hyperlink below. There is also a link to the E-Tool within the manuscript.
Spinal cord stimulation (SCS) is a recognized management option for patients with refractory neuropathic pain. Despite randomized controlled trials reporting the effectiveness of SCS, there is a lack of long-term data reflecting usual SCS practice. The aim of this study is to present the long-term outcomes of a cohort of patients from a single centre undertaking SCS with devices from a single manufacturer.
Intrathecal (IT) drug infusion is an appropriate and necessary tool in the algorithm to treat refractory cancer and noncancer pain. The decision-making steps/methodology for selecting appropriate patients for implanted targeted drug delivery systems is controversial and complicated. Therefore, a consensus on best practices for determining appropriate use of IT drug infusion may involve testing/trialing this therapy before implantation.
Patients with "refractory angina" (RA) unsuitable for coronary revascularization experience high levels of hospitalization and poor health-related quality of life. Randomized trials have shown spinal cord stimulation (SCS) to be a promising treatment for chronic stable angina and RA; however, none has compared SCS with usual care (UC). The aim of this pilot study was to address the key uncertainties of conducting a definitive multicenter trial to assess the clinical and cost-effectiveness of SCS in RA patients, i.e., recruitment and retention of patients, burden of outcome measures, our ability to standardize UC in a UK NHS setting.
Neuropathic pain commonly affects the back and legs and is associated with severe disability and psychological illness. It is unclear how patients with predominantly neuropathic pain due to failed back surgery syndrome (FBSS) compare with patients with other chronic pain conditions.
The Implementation of Persistent Spinal Pain Syndrome (PSPS): Mechanism-based recommendations https://onlinelibrary.wiley.com/doi/epdf/10.1111/papr.70104 This article builds on the name change of Persistent Spinal Pain Syndrome, where the type 2 variant was formerly known as Failed Back Surgery Syndrome. The type 1 is the same array of conditions but without prior surgery. Why is this article important? PSPS is a collective term for a full range of secondary pain conditions of spinal origin. The traditional anatomical model of understanding spinal pain conditions is not sufficient and often leads to inappropriate treatment such as spinal surgery. We present the PAMC model that is based upon putting the mechanism of pain foremost. The categories generated should improve communication between stakeholders of spinal pain therapy and guide the choice of appropriate therapy.
The PROCO RCT is a multicenter, double-blind, crossover, randomized controlled trial (RCT) that investigated the effects of rate on analgesia in kilohertz frequency (1–10 kHz) spinal cord stimulation (SCS).
The use of neurostimulation for pain has been an established therapy for many decades and is a major tool in the arsenal to treat neuropathic pain syndromes. Level I evidence has recently been presented to substantiate the therapy, but this is balanced against the risk of complications of an interventional technique.
Surgical site infections (SSIs) are associated with significant healthcare costs and morbidity. Limited research exists specific to the prevention of spinal cord stimulation (SCS) SSIs. The objectives of this international survey were to examine current infection control practices for SCS trials and implants and to compare reported responses with evidence-based recommendations.
Spinal cord stimulator (SCS) infections are common (2.5–13%) and may cause harm. It is unclear if a screening trial with definitive leads presents an increased infection risk.
The objective of this study was to follow up patients considered for spinal cord stimulation and assess outcomes and patient selection factors associated with outcome.